文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

呼吸道合胞病毒疫苗和单克隆抗体的价值档案

Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
PubMed 文献 · Vaccine · 2023-07-06

呼吸道合胞病毒(RSV)是全球幼儿急性下呼吸道感染的主要病因,目前尚无获批疫苗。单克隆抗体预防仅限少数极高危婴幼儿,现有产品需多剂次且费用高。候选管线聚焦母体RSV疫苗和长效婴儿单克隆抗体两种被动免疫策略,未来一至三年内可能获批,经济模型提示两者可能具成本效益。

要点

  • RSV是全球幼儿急性下呼吸道感染的主要病因,目前无获批疫苗。
  • 现有单克隆抗体产品仅用于少数极高危婴幼儿,需多剂次且费用高。
  • 候选管线聚焦母体RSV疫苗和长效婴儿单克隆抗体,未来一至三年内可能获批。

核心结论

  • 经济模型提示母体RSV疫苗和长效婴儿单克隆抗体两种被动免疫策略可能具成本效益,取决于最终产品特性。

研究设计与样本

  • 本价值档案由来自学术界、非营利组织、公私合作组织和多边组织的主题专家工作组制定,并与世界卫生组织总部的利益相关者合作。
  • 本价值档案仅使用现有和公开可用的信息。

主要发现

  • RSV是全球幼儿急性下呼吸道感染的主要病因,每年造成数百万疾病和住院以及数万幼儿死亡。
  • 单克隆抗体预防仅用于少数极高危婴幼儿,现有唯一获批产品需多剂次且费用高,不适合RSV疾病负担最重的低收入环境。
  • 候选管线聚焦两种适合低收入环境的被动免疫方法:母体RSV疫苗和长效婴儿单克隆抗体。
  • 未来一至三年内可能有一个或多个候选产品获批。

临床怎么用

  • 有效、高效和公平地交付母体RSV疫苗或长效婴儿单克隆抗体,需要妇幼健康规划与扩大免疫规划之间强有力协调。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory syncytial virus (RSV) is the predominant cause of acute lower respiratory infection (ALRI) in young children worldwide, yet no licensed RSV vaccine exists to help prevent the millions of illnesses and hospitalizations and tens of thousands of young lives taken each year. Monoclonal antibody (mAb) prophylaxis exists for prevention of RSV in a small subset of very high-risk infants and young children, but the only currently licensed product is impractical, requiring multiple doses and expensive for the low-income settings where the RSV disease burden is greatest. A robust candidate pipeline exists to one day prevent RSV disease in infant and pediatric populations, and it focuses on two promising passive immunization approaches appropriate for low-income contexts: maternal RSV vaccines and long-acting infant mAbs. Licensure of one or more candidates is feasible over the next one to three years and, depending on final product characteristics, current economic models suggest both approaches are likely to be cost-effective. Strong coordination between maternal and child health programs and the Expanded Program on Immunization will be needed for effective, efficient, and equitable delivery of either intervention. This 'Vaccine Value Profile' (VVP) for RSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships and multi-lateral organizations, and in collaboration with stakeholders from the WHO headquarters. All contributors have extensive expertise on various elements of the RSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fleming JA, Baral R, Higgins D, et al. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies. Vaccine. 2023. PMID: 37422378. doi:10.1016/j.vaccine.2022.09.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。